Both in Biotechnology
Recursion Pharmaceuticals vs Beam Therapeutics
Over the past year RXRX returned −22.4% and BEAM returned +22.2%; their daily moves had a correlation of 0.59.
RXRX −22.4% BEAM +22.2%Growth of $1, one year, split-adjusted
| Metric | RXRX | BEAM |
|---|---|---|
| Price | $3.88 | $27.79 |
| Market cap | $2.32B | $2.87B |
| Today | +5.43% | +5.54% |
| 1 month | −16.2% | +10.1% |
| 6 months | +13.1% | −14.1% |
| Year to date | −5.1% | +0.3% |
| 1 year | −28.7% | +14.6% |
| Revenue growth (YoY) | +258.5% | −94.2% |
| Gross margin | 45.9% | 100.0% |
| Net margin | −641.6% | −25036.3% |
| P/E (TTM) | — | — |
| Price / sales | 34.0× | 18.4× |
| Net cash | $538.0M | $1.05B |
| Dividend yield | — | — |
| Volatility (60d) | 95.9% | 64.2% |
| Short % of float | 37.5% | 32.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).